Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, HER2-negative breast cancer: A network meta-analysis

Researchers performed a meta-analysis to evaluate the effectiveness and safety of 16 different neoadjuvant treatment protocols in patients with HR+ HER2- breast cancer. After evaluating data from 5,752 patients, the researchers concluded that the anthracycline-containing chemotherapy plus olaparib and anthracycline-containing chemotherapy plus nivolumab groups demonstrated superior efficacy as neoadjuvant therapy in this disease type. However, they stated that further research, especially randomized controlled trials, are necessary to validate these findings.